SSSeyedeh Ghazal Shahrokh

Seyedeh Ghazal Shahrokh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyedeh Ghazal Shahrokh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thrombotic microangiopathy in IgA nephropathy: pathophysiology, histopathology, and treatment perspectives

    by Ali Rastegar-Kashkouli, Mohsen Jafari, Seyedeh Ghazal Shahrokh, Amir Mohammad Taravati, Pourya Yousefi, Mohammadreza Jafari

    The current narrative review study aims to provide an overview of thrombotic microangiopathy (TMA) in immunoglobulin A nephropathy (IgAN), with a particular emphasis on its pathophysiology, histopathology, and treatment options. The prevalence and clinical significance of TMA in IgAN may vary across different populations. Estimates suggest that TMA events occur in 2-50% of patients with IgAN. Endothelial injury is a key factor in TMA development in IgAN, triggered by immune complex deposition, complement activation, and potentially hypertension. TMA in IgAN correlates with vascular lesions, including arterial intimal sclerosis, arteriolar lumen reduction, and smooth muscle hypertrophy. Notably, patients with TMA show more intense deposition of C4, C3d, and C5b-9 complements. Treatment involves blood pressure management, immunosuppression, and targeted therapies such as eculizumab.


  • Open Access

    Investigating the potential association between hypertension and cancer: unveiling onco-hypertension as an innovative concept

    by Mohsen Jafari, Ali Rastegar-Kashkouli, Pourya Yousefi, Farzaneh Moammer, Amir Mohammad Taravati, Seyedeh Ghazal Shahrokh, Koushan Rostami, Mohammad Reza Jafari

    Hypertension and cancer show a possible association, with hypertension being a result of cancer and its treatments and also serving as a potential risk factor for the development of cancer. The term "onco-hypertension" describes the presence of hypertension in individuals who have been diagnosed with cancer. Among individuals with cancer, hypertension is the most common coexisting medical condition, occurring in 38% of cases. Cancer-related hypertension involves various mechanisms, including tumor-related factors, coexisting conditions, renal dysfunction, hormonal abnormalities, and stress-related inflammation. Cancer treatments like chemotherapy-targeted therapies and immunotherapies have the potential to influence the regulation of blood pressure through the renin-angiotensin-aldosterone system (RAAS), sodium balance, and fluid retention. Epidemiological studies suggest a potential link between hypertension and specific types of cancer, although the exact reasons and underlying mechanisms remain uncertain. Antihypertensive medications have varying associations with cancer risk. Diuretics are linked to renal cell carcinoma (RCC), thiazide medications to squamous cell carcinoma (SCC), and angiotensin-converting enzyme (ACE) inhibitors to a potential increased risk of lung cancer. However, studies on angiotensin receptor blockers (ARBs) show inconclusive results. Managing onco-hypertension may require pharmacological interventions in addition to lifestyle modifications. Antihypertensive medications commonly used include ACE inhibitors, ARBs, diuretics, calcium channel blockers, and beta-blockers. Factors such as overall health, cancer stage, concomitant medications, treatment interactions, efficacy, tolerability, and side effects guide medication selection.